$213.7 M

ADMA Mkt cap, 18-Jul-2018

$4.7 M

ADMA Biologics Revenue Q3, 2017
ADMA Biologics Net income (Q3, 2017)-15.2 M
ADMA Biologics EBIT (Q3, 2017)-14.4 M
ADMA Biologics Cash, 30-Sep-201713.6 M
ADMA Biologics EV214.6 M

ADMA Biologics Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

3.1 m5.9 m7.2 m10.7 m

Revenue growth, %

93%21%49%

R&D expense

7.7 m

General and administrative expense

8.5 m

Operating expense total

16.2 m

EBIT

(15 m)(16 m)(15.5 m)(17.3 m)

EBIT margin, %

(490%)(271%)(216%)(163%)

Interest expense

618.2 k1.3 m1.8 m2.2 m

Interest income

7.6 k14.2 k37.8 k50.3 k

Pre tax profit

(15.5 m)(17.4 m)(18 m)

Net Income

(15.5 m)(16.8 m)(18 m)(19.5 m)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

1.1 m1.6 m1.5 m1.4 m1.5 m1.3 m1.9 m2.1 m2.3 m2.9 m2.6 m3.4 m4.7 m

R&D expense

1.4 m4.3 m1.8 m1.5 m1.4 m1.5 m2.1 m2 m3.4 m1.7 m1.2 m1.4 m

General and administrative expense

845.3 k1.1 m1.5 m1 m1.3 m1.4 m2.1 m1.7 m1.7 m1.8 m4.3 m4.4 m

Operating expense total

3.6 m7.2 m5.1 m4.4 m4.7 m4.8 m6.5 m6.3 m7.8 m6.7 m8.6 m11.8 m19.2 m

EBIT

(2.5 m)(5.7 m)(3.6 m)(3 m)(3.2 m)(3.5 m)(4.7 m)(4.2 m)(5.5 m)(3.7 m)(5.9 m)(8.4 m)(14.4 m)

EBIT margin, %

(229%)(364%)(239%)(222%)(213%)(268%)(252%)(196%)(242%)(127%)(226%)(247%)(305%)

Interest expense

162.9 k226.9 k342.8 k335.3 k476 k453.4 k449.3 k467.4 k538 k606 k618.5 k642.5 k783 k

Interest income

2.1 k1.8 k3.6 k3.5 k5 k9.8 k11.1 k13.5 k12 k11.6 k18.6 k7.9 k8 k

Pre tax profit

(2.7 m)

Net Income

(2.7 m)(5.9 m)(4 m)(3.4 m)(3.6 m)(4.7 m)(5.1 m)(4.6 m)(6 m)(4.3 m)(6.5 m)(9 m)(15.2 m)

ADMA Biologics Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

26.1 m17.2 m10.4 m9.9 m

Accounts Receivable

384 k924.5 k1 m

Inventories

1.7 m1.7 m3.4 m5 m

Current Assets

31.1 m24.1 m21.3 m21.7 m

Total Assets

32 m27.2 m23.7 m23.7 m

Accounts Payable

2.7 m1.8 m2.1 m2.6 m

Short-term debt

6.1 m

Current Liabilities

3.7 m4.2 m4.2 m11.2 m

Total Debt

6.1 m

Total Liabilities

28.1 m

Additional Paid-in Capital

74.2 m75.5 m88.2 m102.5 m

Retained Earnings

(52.6 m)(69.4 m)(87.4 m)(106.9 m)

Total Equity

21.6 m6 m821 k

Debt to Assets Ratio

0.3 x

Financial Leverage

1.5 x4.5 x28.9 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

5.4 m26.5 m17.9 m14 m16.6 m7.8 m9.2 m8.9 m12.5 m7.9 m8.5 m25.6 m13.6 m

Accounts Receivable

335.1 k484.4 k803.5 k562.2 k351.4 k522.5 k1.2 m944 k826.7 k1.3 m839.9 k2.3 m1.5 m

Inventories

1.2 m984.5 k1.1 m1.5 m1.9 m2.5 m2.8 m4 m4.2 m4.6 m5.3 m13.2 m13.4 m

Current Assets

7.1 m30.8 m26.5 m22.6 m31 m27.1 m25.2 m17.4 m29.5 m25.4 m15.7 m44.3 m31.4 m

PP&E

28.6 m

Goodwill

3.5 m3.5 m

Total Assets

8.7 m32 m27.9 m25.3 m33.9 m29.8 m27.8 m19.7 m31.7 m27.5 m17.6 m84.6 m72.8 m

Accounts Payable

1.5 m2.8 m2.3 m2.4 m1.8 m1.6 m2.2 m2.5 m3.3 m2.8 m3.9 m4.7 m9.2 m

Short-term debt

4.4 m6.7 m6.7 m

Current Liabilities

2.5 m4.3 m3.8 m4.1 m3.8 m3.2 m4.3 m4.3 m5.1 m9.2 m13 m15.6 m13.3 m

Long-term debt

9.4 m14.5 m

Total Debt

4.4 m6.7 m16 m14.5 m

Total Liabilities

9.4 m16 m15.6 m16 m20.5 m20.3 m22.9 m23.1 m27.8 m27.6 m28.4 m57 m59.8 m

Additional Paid-in Capital

47.2 m74.4 m74.8 m75.1 m86.5 m87.3 m87.8 m88.7 m102 m102.2 m102.7 m150.2 m150.7 m

Retained Earnings

(47.9 m)(58.5 m)(62.5 m)(65.9 m)(73.1 m)(77.7 m)(82.8 m)(92 m)(98 m)(102.4 m)(113.5 m)(122.5 m)(137.7 m)

Total Equity

15.9 m12.3 m9.2 m13.4 m9.5 m4.9 m3.9 m(10.8 m)27.7 m13 m

Debt to Equity Ratio

1.1 x

Debt to Assets Ratio

0.2 x

Financial Leverage

2 x2.3 x2.7 x2.5 x3.1 x5.7 x8.1 x-1.6 x3.1 x5.6 x

ADMA Biologics Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(15.5 m)(16.8 m)(18 m)(19.5 m)

Depreciation and Amortization

247.9 k469.8 k469.6 k

Accounts Receivable

(384 k)(540.5 k)(93.6 k)

Inventories

1.7 m(39.7 k)(1.7 m)(1.6 m)

Accounts Payable

2.7 m(937.8 k)308.7 k476.8 k

Cash From Operating Activities

13.6 m(14.7 m)(15.4 m)(18.3 m)

Purchases of PP&E

(2.3 m)(26.1 k)(73.4 k)

Cash From Investing Activities

(4 m)(1.7 m)904.6 k

Cash From Financing Activities

9.8 m10.4 m16.8 m

Interest Paid

785.5 k1.3 m1.5 m

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017

Net Income

(2.7 m)(5.9 m)(4 m)(3.4 m)(3.6 m)(4.7 m)(5.1 m)(4.6 m)(6 m)(4.3 m)(6.5 m)(15.2 m)

Accounts Receivable

803.5 k562.2 k351.4 k522.5 k1.2 m944 k826.7 k1.3 m839.9 k1.5 m

Inventories

1.1 m1.5 m1.9 m2.5 m2.8 m4 m4.2 m4.6 m5.3 m13.4 m

Accounts Payable

2.3 m2.4 m1.8 m1.6 m2.2 m2.5 m3.3 m2.8 m3.9 m9.2 m

ADMA Biologics Ratios

USDY, 2017

EV/EBIT

-14.9 x

Revenue/Employee

51.4 k

Debt/Equity

1.1 x

Debt/Assets

0.2 x

Financial Leverage

5.6 x
Report incorrect company information